ScreenerHero

ENSCEnsysce Biosciences Inc. Common Stock

NAS · US · Healthcare · Biotechnology · ensysce.com
0.3733USD-3.79%Mkt Cap: 7.26M $P/E: —

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activa…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap7.26M $
Enterprise Value6.54M $
Revenue (TTM)4.50M $
Gross Profit-5.88M $
Net Income (TTM)-10.18M $
Revenue/Share0.6790 USD
Last Price0.3733 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.56
PEG—
EV/EBITDA—
EV/Revenue1.45
P/S1.63
P/B-7.87
EPS (TTM)-2.56
EPS (Forward)-0.05
52W Range
0.23006% of range2.750
52W High2.750 USD
52W Low0.2300 USD
Profitability
Gross Margin-130.56%
Oper. Margin-221.28%
EBITDA Margin0.00%
Profit Margin-280.48%
ROE-316.63%
ROA-136.54%
Growth
Revenue Growth-15.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.81M $
CapEx (TTM)123.64K $
FCF Margin-99.95%
FCF Yield-61.93%
Net Debt-479.86K $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.10
Current Ratio0.70
Quick Ratio0.27
Book Value/Sh-0.0480 USD
Cash/Share0.0350 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateDec 6, 2024
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.250 USD
Upside (mean)+2110.0%
Target Range8.250 USD – 8.250 USD
# Analysts1
Ownership
Shares Out.19.46M
Float19.44M
Insiders4.72%
Institutions4.65%
Short Interest
Short Ratio0.2d
Short % Float1.25%
Short % Out.1.24%
Shares Short191.29K
Short (prev mo.)182.35K
Technical
SMA 500.3101 (+20.4%)
SMA 2000.6899 (-45.9%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)25.48M
Avg Vol (10d)5.58M
Technical Indicators
RSI (14)53.0
MACD0.0271
MACD Signal0.0291
MACD Hist.-0.0020
BB Upper0.5246 USD
BB Middle0.3508 USD
BB Lower0.1770 USD
BB Width99.09%
ATR (14)0.0764 USD
Vol Ratio (20d)0.02x